Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

Novartis aims to lead immuno-oncology category

Firm believes its immuno-oncology pipeline will help it overtake leader Roche

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

AZ pushes immuno-oncology duo into phase III

MEDI4736 and tremelimumab achieved disease control in 48% of NSCLC patients

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

- PMLiVE

Pfizer launches lupus study with 23andMe

Aims to enroll 5,000 patients into new geneticresearch study

UK flag

London life science growth boosted by Takeda

Japanese firm adds to recent surge in pharma spending in the capital

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Pfizer eyes sepsis therapy via a stake in AM-Pharma

US firm continues bumper 2015 for mergers and acquisitions

- PMLiVE

GSK shelves ViiV sale as it lays out growth strategy

Firm now bullish on the HIV joint pharma project’s prospects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links